Precision BioSciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Precision BioSciences generated cash of -$84,114,000, which is less than the previous year. Cash used in financing activities reached the amount of $5,387,000 last year. Net change in cash is therefore -$72,898,000.
Cash Flow
| 2017 | -24.16M | -5.51M | -937K |
|---|---|---|---|
| 2018 | -51.72M | -15.66M | 107.77M |
| 2019 | -71.01M | -24.66M | 173.37M |
| 2020 | -87.38M | -5.03M | 1.32M |
| 2021 | -10.85M | -5.80M | 70.52M |
| 2022 | -45.75M | -3.31M | 94.98M |
| 2023 | -84.11M | 5.82M | 5.38M |
DTIL Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 189.57M | 143.66M | 89.79M | 180.88M | 103.19M | 62.80M | 93.42M |
Operating activities | |||||||
Net income | -61.31M | -111.63M | -30.60M | -109.00M | -92.87M | -46.03M | -21.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 8.25M | 9.00M | 10.19M | 9.81M | 5.31M | 2.35M | 1.43M |
Stock-based compensation expense | 14.04M | 19.19M | 16.51M | 13.78M | 8.94M | 0 | 419K |
| Deferred income tax benefit | 14.04M | 19.19M | 16.51M | 13.78M | 8.94M | 0 | 419K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -181K | -232K | 9.51M | -9.03M | -441K | -523K | 0 |
Inventories | 0 | 0 | 4.30M | 8.01M | 5.28M | -5.94M | 0 |
Accounts payable | 1.50M | 153K | 867K | -1.45M | 667K | -673K | 864K |
Cash generated by operating activities | -84.11M | -45.75M | -10.85M | -87.38M | -71.01M | -51.72M | -24.16M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.27M | -3.31M | -5.80M | -5.03M | -24.66M | -15.67M | -5.56M |
Acquisitions Net | 8M | 0 | 0 | 0 | 0 | 0 | 50K |
Cash generated by investing activities | 5.82M | -3.31M | -5.80M | -5.03M | -24.66M | -15.66M | -5.51M |
Financing activities | |||||||
Common Stock Issued | 4.98M | 74.34M | 60.47M | 1.32M | 135.18M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -952K |
Repayments of term debt | 0 | 19.80M | -2.5M | 0 | 39.55M | 0 | 0 |
Cash used in financing activities | 5.38M | 94.98M | 70.52M | 1.32M | 173.37M | 107.77M | -937K |
Net Change In Cash | -72.89M | 45.91M | 53.86M | -91.08M | 77.69M | 40.39M | -30.62M |
Cash at end of period | 116.67M | 189.57M | 143.66M | 89.79M | 180.88M | 103.19M | 62.80M |
| Data source | Data source | Data source | Data source | Data source |